Novo Integrated Sciences, Inc. (NVOS)
OTCMKTS
· Delayed Price · Currency is USD
0.0033
+0.0028 (560.00%)
Jul 11, 2025, 4:00 PM EDT
Novo Integrated Sciences Revenue
In the fiscal year ending August 31, 2024, Novo Integrated Sciences had annual revenue of $13.29M with 5.75% growth. Novo Integrated Sciences had revenue of $3.08M in the quarter ending August 31, 2024, a decrease of -6.74%.
Revenue
13.29M
Revenue Growth
+5.75%
P/S Ratio
0.00
Revenue / Employee
69.97K
Employees
264
Market Cap
65.11K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 13.29M | 722.34K | 5.75% |
| Aug 31, 2023 | 12.57M | 834.08K | 7.11% |
| Aug 31, 2022 | 11.74M | 2.43M | 26.14% |
| Aug 31, 2021 | 9.31M | 1.44M | 18.38% |
| Aug 31, 2020 | 7.86M | -1.56M | -16.57% |
| Aug 31, 2019 | Pro | Pro | Pro |
| Aug 31, 2018 | Pro | Pro | Pro |
| Aug 31, 2017 | Pro | Pro | Pro |
| Aug 31, 2016 | Pro | Pro | Pro |
| Aug 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 215.62M |
| Elite Pharmaceuticals | 84.04M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Novo Integrated Sciences News
- 7 months ago - Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results - Business Wire
- 1 year ago - Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results - Business Wire
- 1 year ago - What's Going On With Novo Integrated Sciences Stock On Friday? - Benzinga
- 1 year ago - Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program - Business Wire
- 1 year ago - Novo Integrated Sciences: A Coil Spring Ready To Explode - Seeking Alpha
- 1 year ago - Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program - Business Wire
- 1 year ago - Novo Integrated Sciences' Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million - Business Wire
- 1 year ago - Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products - Business Wire